We are proud to announce the publication in npj Vaccines of a pre-clinical ferret study that found no evidence the G-strain mutation of SARS-CoV-2 would adversely impact the efficacy of #COVID19 vaccine candidate INO-4800. #DNAMedicine #DNAVaccine https://t.co/1zldNj53E2
— INOVIO Pharmaceuticals (@InovioPharma) October 8, 2020
We are honored to accept the "Best Therapeutic Vaccine Award" from the 13th Annual Vaccine Industry Excellence Awards for our HPV DNA medicine VGX-3100 targeting HPV-caused pre-cancers! #DNAMedicine #HPV #ViEAwards #WorldVaccineCongress pic.twitter.com/imlPVnq0IE
— INOVIO Pharmaceuticals (@InovioPharma) October 1, 2020
INOVIO reports FDA partial clinical hold for planned Phase 2/3 Trial of COVID-19 vaccine candidate INO-4800. Read more: https://t.co/0EmivBvwQV
— INOVIO Pharmaceuticals (@InovioPharma) September 28, 2020
INOVIO is excited to be part of the #ESMO2020 Congress with interim combo Phase 2 data in HPV-associated HNSCC. See more: https://t.co/7U7kLP5oQD #DNAMedicine #HPV #cancer @myESMO
— INOVIO Pharmaceuticals (@InovioPharma) September 18, 2020
Thermo Fisher's own plasmid manufacturing process will be used to produce INO-4800. Our goal is to manufacture 1 million doses of INO-4800 in 2020 and 100 million doses in 2021. #DNAVaccine #COVID19
— INOVIO Pharmaceuticals (@InovioPharma) September 8, 2020
INOVIO is excited to have @ThermoFisher join our Manufacturing Consortium for our #COVID19 #DNAVaccine candidate, INO-4800. Read more here: https://t.co/xtdG7Ydcpd pic.twitter.com/6gTjCq7Q6C
— INOVIO Pharmaceuticals (@InovioPharma) September 8, 2020
Robb lives with Recurrent Respiratory Papillomatosis (#RRP), a rare, debilitating, & potentially life-threatening disease caused by #HPV genotypes 6/11. RRP is currently incurable but we're on a mission to use #DNAMedicines to provide treatment options. https://t.co/27S5snNMNK
— INOVIO Pharmaceuticals (@InovioPharma) August 31, 2020
August is National Immunization Awareness Month & an important reminder of the significant advancements we’ve seen in vaccination development because of #COVID19. Learn more about our COVID-19 DNA vaccine candidate: https://t.co/WwtiRRhG71 #DNAVaccines #DNAMedicines #Vax2Protect pic.twitter.com/jLdjwbByXc
— INOVIO Pharmaceuticals (@InovioPharma) August 27, 2020
Approximately 7 million #HPV infections occur each year with high-risk HPV genotypes 16/18, which can lead to cancer. INOVIO’s #DNAMedicines are delivered directly into cells so that the body fights disease from within by producing a natural immune to fight back. #DNAVaccines pic.twitter.com/ERZyVU4ZR1
— INOVIO Pharmaceuticals (@InovioPharma) August 25, 2020
Over the next few days, the @WHO is meeting to discuss the adoption of #DNAVaccines guidelines to assure the quality, safety and efficacy of DNA vaccine candidates. This is an important step forward in powering a new decade of #DNAMedicines. Learn more: https://t.co/MpUzSH8339 pic.twitter.com/pffSzFGwKE
— INOVIO Pharmaceuticals (@InovioPharma) August 24, 2020
In this @HPV_World article, Dr. Prakash K. Bhuyan, INOVIO VP of Clinical Development, HPV Therapeutics, discusses why INOVIO’s #DNAImmunotherapies may help fill a critical gap in the treatment of vulvar HSIL, an #HPV-related disease: https://t.co/KHlsXdQf3E #DNAMedicines
— INOVIO Pharmaceuticals (@InovioPharma) August 17, 2020
INO-4800’s animal challenge data shows vaccine-induced responses driving immunity against the G614 variant of #COVID19, which has emerged with greater infectivity & accounts for >80% of newly circulating virus cases. Learn more: https://t.co/Oag6hoHzXS #DNAMedicines #DNAVaccines pic.twitter.com/k7RR3P3piv
— INOVIO Pharmaceuticals (@InovioPharma) August 14, 2020
#DYK: new research highlights the role of #tcell responses in developing an effective #COVID19 vaccine? Read why here: https://t.co/9LSmjCMngD #DNAMedicines #DNAVaccines pic.twitter.com/uPbNH1Jqn4
— INOVIO Pharmaceuticals (@InovioPharma) August 12, 2020
INOVIO recently announced our DNA vaccine demonstrated long-term protection in non-human primates challenged with SARS-CoV-2, the virus that causes #COVID19, 13 weeks after the last vaccination. Read more: https://t.co/eWluOnc2t2 #DNAMedicines #DNAVaccines pic.twitter.com/j1KGQwMJ7H
— INOVIO Pharmaceuticals (@InovioPharma) August 11, 2020
Today INOVIO announced second quarter 2020 financial results and mid-year updates for our #DNAMedicines, #DNAVaccines and #DNAImmunotherapies. We’re excited to share milestones here: https://t.co/dk52CLvIVM $INO pic.twitter.com/MhBQkaORMk
— INOVIO Pharmaceuticals (@InovioPharma) August 10, 2020
Dr. Kate Broderick, INOVIO SVP and R&D Lead, was interviewed on @FoxNews about INOVIO’s #COVID19 DNA vaccine candidate’s recent animal challenge study results and why they’re promising to her as a scientist and mom. Watch here: https://t.co/axmFbUAOWZ #DNAVaccines #DNAMedicines
— INOVIO Pharmaceuticals (@InovioPharma) July 31, 2020
INOVIO’s #COVID19 DNA vaccine candidate, part of the Operation Warp Speed program, showed positive results in a non-human study 13 weeks after the last vaccination. Read more in @Reuters: https://t.co/dtQbfAA8ib #DNAMedicines #DNAVaccines
— INOVIO Pharmaceuticals (@InovioPharma) July 30, 2020
In this @6abc interview, Dr. Kate Broderick, INOVIO SVP and R&D Lead, discusses the role activating T cells could have in a #COVID19 vaccine. One key feature of INOVIO's DNA vaccines is the ability to generate balanced antibody & T cell immune responses #DNAMedicines #DNAVaccines pic.twitter.com/trcpZJAt1W
— INOVIO Pharmaceuticals (@InovioPharma) July 30, 2020
Results from an animal challenge of INOVIO’s #COVID19 DNA vaccine candidate were published in the non-peer reviewed online preprint site @biorxivpreprint & have been submitted to a peer-reviewed medical journal. See manuscript: https://t.co/CRpZbDb0f4 #DNAVaccines #DNAMedicines pic.twitter.com/OOvePn5JNF
— INOVIO Pharmaceuticals (@InovioPharma) July 30, 2020
INO-4800, INOVIO’s #COVID19 DNA vaccine candidate, showed positive results in protecting non-human primates from a live virus challenge 13 weeks after the last vaccination. See the full release here: https://t.co/L4AV19q0dT #DNAMedicines #DNAVaccines pic.twitter.com/vaUQNdGUQi
— INOVIO Pharmaceuticals (@InovioPharma) July 30, 2020
Dr. Kate Broderick, INOVIO SVP and R&D Lead, was interviewed in @TheHill about INOVIO’s contribution to the #COVID19 vaccine race and what the world can expect from our #DNAMedicines technology. Read more: https://t.co/UACSJHI3y6 #DNAVaccines
— INOVIO Pharmaceuticals (@InovioPharma) July 29, 2020
The @US_FDA granted orphan drug designation to INO-3107, INOVIO’s DNA medicine being evaluated in a Phase 1/2 trial for treatment of recurrent respiratory papillomatosis (#RRP). Read more about what this designation means: https://t.co/orMENyq8bK #DNAMedicines #DNAImmunotherapies pic.twitter.com/1PSsnTOfRu
— INOVIO Pharmaceuticals (@InovioPharma) July 29, 2020
Dr. Jeffrey Skolnik, INOVIO VP of Clinical Development, was interviewed by @AJMC_Journal in their #ASCO20 evidence-based #oncology feature. Read what he shared about INOVIO’s glioblastoma multiforme (#GBM) candidate here: https://t.co/tlLNYmPmH1 #DNAMedicines #DNAImmunotherapies pic.twitter.com/R0X8icD98i
— INOVIO Pharmaceuticals (@InovioPharma) July 24, 2020
Today on #GBMDay, hear more about glioblastoma multiforme (#GBM) treatment considerations and the potential role of INOVIO’s #DNAImmunotherapy in this excerpt from our recent #DNAMedicines webinar: https://t.co/icwB4Hkp5J
— INOVIO Pharmaceuticals (@InovioPharma) July 22, 2020
We're proud to participate in the @IPVSociety #IPVC2020 conference to share data from our EACH-WOMAN project w/ @Optum on the effectiveness & safety of standard of care treatment for precancerous cervical dysplasia, often caused by #HPV 16/18 https://t.co/L9rYIqMppB #DNAMedicines
— INOVIO Pharmaceuticals (@InovioPharma) July 21, 2020
INOVIO CEO Dr. J. Joseph Kim spoke with Bloomberg @BW on their #podcast about the Phase 1 interim data for our #COVID19 DNA vaccine candidate and what’s next for Phase 2/3. Listen here: https://t.co/fDeAR5o8mh #DNAVaccines #DNAMedicines pic.twitter.com/RNjVzdQ4a4
— INOVIO Pharmaceuticals (@InovioPharma) July 20, 2020
INOVIO and @IVIHeadquarters in partnership with Seoul National University Hospital dosed the first patient in a Phase 1/2 clinical trial of INOVIO's #COVID19 DNA vaccine candidate in South Korea. #DNAVaccines #DNAMedicines pic.twitter.com/7MXlSnSi8M
— INOVIO Pharmaceuticals (@InovioPharma) July 17, 2020
In our webinar, INOVIO CEO Dr. J. Joseph Kim and Dr. David Weiner, EVP and Director at @TheWistar, INOVIO Director, discussed the history of #DNAMedicines and #DNAVaccines, and what makes them unique. Watch here: https://t.co/WHglQucPOA #COVID19 #ImmunoOncology #Cancer
— INOVIO Pharmaceuticals (@InovioPharma) July 13, 2020
#ICYMI: In this video, Dr. Kate Broderick, INOVIO SVP and R&D Lead, speaks with Dr. Stanley Plotkin, Emeritus Professor and INOVIO Scientific Advisory Board Member, about the potential advantages of #DNAVaccines in response to #COVID19: https://t.co/O930KgAuIs #DNAMedicines
— INOVIO Pharmaceuticals (@InovioPharma) July 9, 2020
Dr. Kate Broderick, INOVIO SVP, R&D Lead, is encouraged by the interim Phase 1 data for INOVIO’s #COVID19 DNA vaccine candidate. See what she said here in @SDUT: https://t.co/IdBenAoD9Z #DNAMedicines #DNAVaccines
— INOVIO Pharmaceuticals (@InovioPharma) July 2, 2020
In this @NHKWORLD_news story, Dr. Kate Broderick, INOVIO SVP, R&D Lead, shares her reaction to positive interim Phase 1 data for INOVIO’s #COVID19 DNA vaccine, along with what’s next for trials: https://t.co/5nKzSKb4lA #DNAMedicines #DNAVaccines pic.twitter.com/ZsgRTCwBoP
— INOVIO Pharmaceuticals (@InovioPharma) July 2, 2020
In this @6abc story, learn about INOVIO’s COVID-19 DNA vaccine candidate selection for Operation Warp Speed and hear from CEO Dr. J. Joseph Kim about why he is optimistic about INOVIO's Phase 1 interim #COVID19 data: https://t.co/q2oIbvUMrA #DNAVaccines #DNAMedicines
— INOVIO Pharmaceuticals (@InovioPharma) July 1, 2020
See INOVIO’s SVP of R&D Dr. Kate Broderick discuss the development of INO-4800, INOVIO’s #COVID19 DNA vaccine candidate, in this @WSJ video hosted by Daniela Hernandez, featuring Dr. Anthony Fauci and other leading scientists: https://t.co/4MUq1gPBl9 #DNAVaccines#DNAMedicines
— INOVIO Pharmaceuticals (@InovioPharma) July 1, 2020
INOVIO CEO Dr. J. Joseph Kim spoke with the @WSJ about positive Phase 1 interim data released yesterday for INOVIO’s #COVID19 DNA vaccine candidate. Learn more here: (log-in required): https://t.co/bOmZrb2qWj #DNAMedicines
— INOVIO Pharmaceuticals (@InovioPharma) July 1, 2020
Today INOVIO announced interim Phase 1 data for INO-4800, our COVID-19 DNA vaccine candidate & its selection in Operation Warp Speed. Learn more about the safety and preliminary response results, along with animal challenge data: https://t.co/OoMAHEYd7f #DNAMedicines #DNAVaccines pic.twitter.com/bkdpfO7jtT
— INOVIO Pharmaceuticals (@InovioPharma) June 30, 2020
INOVIO announced we’ve been awarded $71 million from the U.S. @DeptofDefense to support large-scale manufacturing of INOVIO’s CELLECTRA® 3PSP device, which is used to deliver INOVIO’s COVID-19 DNA vaccine candidate. Details: https://t.co/71byTCyNRh #DNAMedicines #DNAVaccines pic.twitter.com/1rKrFHQM4m
— INOVIO Pharmaceuticals (@InovioPharma) June 23, 2020
INOVIO has moved into Phase 1/2 #clinicaltrials for INO-3107 and is seeking participants with HPV-6 and/or HPV-11 associated recurrent respiratory papillomatosis (RRP). For details, click here: https://t.co/cLqy99T8NN #DNAMedicines #DNAImmunotherapies pic.twitter.com/2eqVWlSdim
— INOVIO Pharmaceuticals (@InovioPharma) June 22, 2020
INOVIO CEO Dr. J Joseph Kim was on an @IAmBiotech panel with experts from @JNJInnovation, @Chimerix, @Novartis, @ABatemanHouse & @ArthurCaplan to discuss bioethics through the lens of a pandemic. Watch on @StatNews: https://t.co/0rHs7whtxq #DNAMedicines #DNAVaccines
— INOVIO Pharmaceuticals (@InovioPharma) June 18, 2020
INOVIO pairs rapid design and groundbreaking delivery to design urgently needed, effective #DNAMedicines, including #DNAImmunotherapies & #DNAVaccines. Learn how we’re using our approach to combat global health concerns on our YouTube channel: https://t.co/41lhZ6gQJ1 #COVID19
— INOVIO Pharmaceuticals (@InovioPharma) June 17, 2020
We’re proud INOVIO’s DNA vaccine and our work to combat COVID-19 are featured in @IAmBiotech's #BeyondImagination series blog post. Check it out here. https://t.co/L9cfaXuHM9 #DNAMedicines #DNAVaccines
— INOVIO Pharmaceuticals (@InovioPharma) June 16, 2020
Tim Herring, MPH, INOVIO Senior Epidemiologist, presented at a virtual @JeffAcCommons seminar titled “COVID-19: Pharmaceutical Vaccine Development – General Process & Focus on a DNA-based Vaccine.” Watch here: https://t.co/rp4dFzkaT1 #DNAMedicines #DNAVaccines pic.twitter.com/t1ZA8l4bgq
— INOVIO Pharmaceuticals (@InovioPharma) June 15, 2020
In this video interview with @WIRED, INOVIO CEO Dr. J. Joseph Kim speaks with Dr. Seema Yasmin about INOVIO’s COVID-19 DNA vaccine candidate and updates on current trials: https://t.co/z4C2vIV5JY #DNAMedicines #DNAVaccines
— INOVIO Pharmaceuticals (@InovioPharma) June 11, 2020
In this @sdut article, learn more about the process of developing a #COVID19 vaccine and what makes INOVIO’s COVID-19 DNA vaccine candidate stand out: https://t.co/N9ENNOuTN8 #DNAVaccines #DNAMedicines
— INOVIO Pharmaceuticals (@InovioPharma) June 11, 2020
INOVIO is focused on serving people with urgent health needs. One area we are studying is the role #DNAMedicines can have for newly diagnosed glioblastoma patients. See our data: https://t.co/QN6X38Zk8d #BrainTumorAwarenessMonth #DNAImmunotherapy pic.twitter.com/VMA17dCPAu
— INOVIO Pharmaceuticals (@InovioPharma) May 29, 2020
Learn more about how INOVIO is creating precisely designed plasmids with our technology: https://t.co/AIw0WzOwe0 #DNAMedicines pic.twitter.com/CzL8n9tVOp
— INOVIO Pharmaceuticals (@InovioPharma) May 28, 2020
The @WHO and @CEPIVaccines selected two vaccine candidates for COVID-19 to be tested for efficacy in Australia. One of those is INOVIO’s DNA vaccine candidate for #COVID19. Read more on @CSIRO’s blog. #DNAVaccines #DNAMedicines https://t.co/Zijmn9mp3C
— INOVIO Pharmaceuticals (@InovioPharma) May 28, 2020
Today we announced an INOVIO study published in peer-reviewed journal @NatureComms about the robust preclinical immune response, including both neutralizing antibodies and T cell responses, of INOVIO’s COVID-19 DNA vaccine: https://t.co/nrysBJAO70 #DNAMedicines #DNAVaccines pic.twitter.com/MJsJSEMOXL
— INOVIO Pharmaceuticals (@InovioPharma) May 20, 2020
INOVIO released data for newly diagnosed #glioblastoma multiforme (#GBM) patients who received our DNA medicine INO-5401 in combination w/ a PD-1 inhibitor. Results will be presented at #ASCO20 Virtual Scientific Program: https://t.co/4I8DPlY5qJ #DNAMedicines #DNAImmunotherapy pic.twitter.com/b7QTxBDWUE
— INOVIO Pharmaceuticals (@InovioPharma) May 14, 2020
Today #INOVIO reported Q1 2020 financial results and important company updates about our DNA vaccines for COVID-19, and diseases associated with #HPV and #cancer. See results here: https://t.co/xR1LfHggOw #DNAVaccines #DNAMedicines $INO pic.twitter.com/11ONQRXTPb
— INOVIO Pharmaceuticals (@InovioPharma) May 11, 2020
We published data from our completed Phase 1b study with INO-5150 that demonstrated a slowing of Prostate-Specific Antigen Doubling Time (PSADT), a measure of clinical impact, in men with biochemically relapsed prostate cancer. Link: https://t.co/qErsL0cemz #DNAMedicines
— INOVIO Pharmaceuticals (@InovioPharma) May 8, 2020
What used to take years, INOVIO is doing in months. In this @WashingtonPost article, read about how quickly we designed our #COVID19 DNA vaccine candidate and what we’re doing to move forward with unprecedented speed: https://t.co/ZLvBarw4Ex #DNAVaccines #DNAMedicines pic.twitter.com/uUfs7vp0Go
— INOVIO Pharmaceuticals (@InovioPharma) May 3, 2020
With new funding from @CEPIVaccines, INOVIO will expand our existing DNA manufacturing agreement with Richter-Helm BioLogics to support large-scale manufacturing of our COVID-19 DNA vaccine candidate. Read more: https://t.co/GCruws65xG #DNAVaccines #DNAMedicines #COVID19 pic.twitter.com/BBJs7DMc9X
— INOVIO Pharmaceuticals (@InovioPharma) May 1, 2020
Today INOVIO and GeneOne Life Science announced positive interim data through week 16 of Phase 1/2a clinical data of INOVIO’s DNA vaccine INO-4700 for MERS #coronavirus. Read more here: https://t.co/yZxHqft1uA #DNAMedicines #DNAVaccines pic.twitter.com/E6YinzqZrs
— INOVIO Pharmaceuticals (@InovioPharma) April 28, 2020
We provided 40 healthy volunteers with the 1st dose of our #COVID19 DNA vaccine candidate. With our Phase 1 U.S. clinical trial enrollment complete, interim immune responses & safety results are excepted in late-June. Read more: https://t.co/JXEM4YBSbb #DNAVaccines #DNAMedicines pic.twitter.com/g3jtJw61JU
— INOVIO Pharmaceuticals (@InovioPharma) April 28, 2020
Eleven trial volunteers have been dosed with our #COVID19 DNA vaccine candidate. Last night one of those volunteers was interviewed on @NBCNightlyNews. Watch the segment here to learn more about our #DNAVaccines: https://t.co/V73mvuL9th #DNAMedicines
— INOVIO Pharmaceuticals (@InovioPharma) April 24, 2020
Our CEO Joseph Kim was interviewed on PBS @NewsHour sharing an update on our COVID-19 DNA vaccine candidate. Watch the segment and learn more about #DNAMedicines here: https://t.co/ycHCQqjhp2 #DNAVaccines #COVID19
— INOVIO Pharmaceuticals (@InovioPharma) April 22, 2020
Today @IVIHeadquarters announced @CEPIVaccines granted funding to INOVIO to work with IVI and the Korea National Institute of Health for a Phase 1/2 clinical trial of our #COVID19 DNA vaccine candidate in South Korea. Read more: https://t.co/dZmlcFkm4q #DNAMedicine #DNAVaccines pic.twitter.com/LtgrjqodNu
— INOVIO Pharmaceuticals (@InovioPharma) April 16, 2020
INOVIO is at the forefront of the fight against #COVID19. In this @cenmag article, our CEO Joseph Kim talks about DNA vaccines and working to bring them to market: https://t.co/zWLLLCoglI #DNAVaccines #DNAMedicines pic.twitter.com/CDrRxKVIiQ
— INOVIO Pharmaceuticals (@InovioPharma) April 5, 2020
Our coronavirus R&D lead Dr. Kate Broderick participated in a press conference with the Mayor of San Diego about our progress on a #COVID19 vaccine and how the world is coming together. #DNAMedicines #DNAVaccines https://t.co/SGMIQ5YTpd pic.twitter.com/FTVM9K9i66
— INOVIO Pharmaceuticals (@InovioPharma) March 30, 2020
To learn more about our #DNAMedicines, click here: https://t.co/LRw7vSV4aY #INOVIO
— INOVIO Pharmaceuticals (@InovioPharma) March 30, 2020
INOVIO today announced positive interim results with our lead DNA medicine candidate VGX-3100 from our Phase 2 study in patients with HPV-associated precancerous vulvar dysplasia. See the data here: https://t.co/iwAMofOQtG #HPV #DNAMedicines #INOVIO #vulvardysplasia pic.twitter.com/DLSM8NWmHd
— INOVIO Pharmaceuticals (@InovioPharma) March 30, 2020
Learn more about INOVIO’s approach to #DNAMedicines here: https://t.co/6EtDKQa1MS #INOVIO #DNAVaccines
— INOVIO Pharmaceuticals (@InovioPharma) March 27, 2020
Last night on @CNN, Bill Gates discussed what the world is learning from #COVID19 and how his foundation is helping companies like #INOVIO build DNA vaccines in a new way: https://t.co/nJL68GPJBg #DNAMedicines #DNAVaccines
— INOVIO Pharmaceuticals (@InovioPharma) March 27, 2020
$INO today announced positive interim results with our lead DNA medicine candidate VGX-3100 from our Phase 2 study in patients with HPV-associated precancerous anal dysplasia. See the data here: https://t.co/lHTtgTcS4p #HPV #DNAMedicines pic.twitter.com/x31azHzf43
— INOVIO Pharmaceuticals (@InovioPharma) March 26, 2020
The Department of Defense awarded @OlogyBio a grant to partner with INOVIO to manufacture a #COVID19 vaccine. Read more here: https://t.co/TRJ1qh5JmZ $INO
— INOVIO Pharmaceuticals (@InovioPharma) March 24, 2020
Today we announced a $5M grant from the Bill & Melinda Gates Foundation to accelerate the testing and scale-up of our CELLECTRA® 3PSP smart device for the intradermal delivery of INO-4800, our DNA vaccine candidate for COVID-19. #INOVIO #COVID19 Read more: https://t.co/mekLlby2Va
— INOVIO Pharmaceuticals (@InovioPharma) March 12, 2020
#INOVIO #INO $INO #COVID19 #DNA #DNAmedicine pic.twitter.com/m0ueIKb24w
— INOVIO Pharmaceuticals (@InovioPharma) March 9, 2020
Highlighting International HPV Awareness Day, we are reminded of the urgent need to combat the human papillomavirus (HPV), a core focus for us at INOVIO. #HPV #INOVIO $INO Read more: https://t.co/ihjPN55Ko6
— INOVIO Pharmaceuticals (@InovioPharma) March 5, 2020
After meeting with President Trump, Vice President Pence, and the U.S. Coronavirus Task Force at the White House, we announced an accelerated timeline for developing DNA vaccine INO-4800 to address COVID-19. $INO #INOVIO #COVID19 Read more: https://t.co/UO2EZ0AjuY
— INOVIO Pharmaceuticals (@InovioPharma) March 3, 2020
Read more about the trial at https://t.co/xDWM1k2i2g and https://t.co/2vqN9JjQxq
— INOVIO Pharmaceuticals (@InovioPharma) November 8, 2019
A toddler’s dwindling voice was chalked up to acid reflux. Her problem was far more serious. https://t.co/Adj5Ng9rKN
— INOVIO Pharmaceuticals (@InovioPharma) April 3, 2019
We’re working with @InovioPharma to develop a vaccine against #COVID19 💉@ELLEmagazine speaks to Dr Kate Broderick about their rapid response to the outbreak 👩⚕️ #InternationalWomensDay https://t.co/JQs89Ef2t3
— CEPI (@CEPIvaccines) March 8, 2020
Given the rapid global spread of the nCoV-2019 virus the world needs to act quickly and in unity to tackle this disease 🌏
We're funding three programmes to develop vaccines against the novel #coronavirus, nCoV-2019 👉https://t.co/2KeMWUjGjk pic.twitter.com/JYALaga8RD
— CEPI (@CEPIvaccines) January 23, 2020
May saw our partners @InovioPharma launch the first in-human trial with their Lassa vaccine candidate🩺
Our Director of Vaccine R&D, Melanie Saville, said: “We welcome Inovio’s work which could pave the way to reducing the great suffering caused” 👉 https://t.co/vvzPxfi7hp pic.twitter.com/hchq4ztLgU
— CEPI (@CEPIvaccines) December 30, 2019
https://twitter.com/CEPIvaccines/status/1132232922906398720
"We expect to finish enrollment of all 40 volunteers before the end of April," Inovio Pharmaceuticals CEO Dr. Joseph Kim told @JimCramer. Inovio is one of two companies to initiate Covid-19 vaccine trials in the U.S. https://t.co/ZK2DFohTLB
— Mad Money On CNBC (@MadMoneyOnCNBC) April 24, 2020
If you want to get a reasonable, clear-eyed summation of what’s probably ahead with Coronavirus, I’ve read a lot about it and I think @jameshamblin’s is the best. https://t.co/0GTP3dQZ3A
— Amanda Mull (@amandamull) February 25, 2020
We are proud to work with so many top notch customers and collaborators on #coronavirus.@InovioPharma @EmilyLeproust #2019nCoV #WeMakeDNA
The global fight against coronavirus – BBC Future https://t.co/vFj83kT82k
— Twist Bioscience (@TwistBioscience) February 10, 2020
Several drugmakers are racing to develop vaccines that could protect against the new respiratory virus originating in China, as fears mount it could spread more widely https://t.co/qPvn9MmJi1
— The Wall Street Journal (@WSJ) January 24, 2020
Philadelphia-based biotech firm Inovio, with a $9 million grant, joins the race to create a coronavirus vaccine https://t.co/kwWvkFldxC pic.twitter.com/bcclWMaCpd
— Bloomberg TV (@BloombergTV) January 27, 2020
After receiving COVID-19’s genetic sequence in January, Inovio Pharmaceuticals put it into their computer algorithm, which designed a vaccine on paper in just three hours. How long will it take before a vaccine is ready? https://t.co/uPuWcIvvEZ pic.twitter.com/IITRd2RVzA
— 60 Minutes (@60Minutes) March 23, 2020
Inovio Pharmaceuticals’ race to create a vaccine began when the genetic sequence of COVID-19 was posted online by Chinese scientists just weeks after the outbreak was identified. https://t.co/tJfgmAnJ00 pic.twitter.com/kawgGgbtZb
— 60 Minutes (@60Minutes) March 22, 2020
Sunday on 60 Minutes: when will a vaccine to prevent COVID-19 — and an anti-viral drug to treat the disease — be ready? https://t.co/hXZvYXi2Rk pic.twitter.com/qTViTyDDwU
— 60 Minutes (@60Minutes) March 20, 2020
We will present our Phase 1b platform study in metastatic #prostatecancer at #SITC2019 this Friday, Poster P387. Read about our PORTER clinical trial, which tests 3 #immunotherapy drug combos. @bmsnews @cancerresearch @inoviopharma @oncovir and CellDex https://t.co/Lpq5YXmV80
— Parker Institute for Cancer Immunotherapy (@parkerici) November 6, 2019
Inovio Eyes Expanded Asian Opportunities, Presence Via Korea Dual Listinghttps://t.co/eUdUqSciAM #PharmaScrip
— Scrip (@PharmaScrip) August 13, 2019
Congrats to @TheWistar’s Dr. Weiner & our partners at @InovioPharma for winning Best Therapeutic Vaccine Award at the #ViEAwards for their #HPV vaccine! pic.twitter.com/3s4vs2flPq
— The Wistar Institute (@TheWistar) April 16, 2019
Congrats to Dr. David Weiner on the 2019 Scientific Achievement Award from @LifeSciencesPA! We @TheWistar are proud of you! pic.twitter.com/nRYcig9uZa
— The Wistar Institute (@TheWistar) March 13, 2019